Earnings Releases·Nov 3, 2026, 8:11 AM ET

Sotera Health — Third Quarter 2026 Earnings Summary

Q3 2026 net revenues rose 4.4% year-over-year to $324.9 million, while net income increased to $58.4 million ($0.20 per share) from $48.4 million ($0.17 per share) in the prior year period; Adjusted EPS grew 12% to $0.29.
Full-year 2026 guidance was reaffirmed with net revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25% on a constant currency basis, alongside a revised foreign currency benefit of 70 basis points.
Segment performance showed strong growth at Sterigenics (8.5% revenue increase) and Nelson Labs (8.8% revenue increase), partially offset by a 12.4% revenue decline at Nordion due to Co-60 harvest timing.
Balance sheet strength improved with a Net Leverage Ratio of 2.9x (down from 3.2x), unrestricted cash rising to $412 million, and a credit rating upgrade from Moody's in October 2026.
Nine-month 2026 net revenues increased 7.7% to $926.3 million, and net income surged to $138.6 million ($0.48 per share) compared to $43.1 million ($0.15 per share) in the prior year period.